CLINICAL TRIALS PROFILE FOR CEFPODOXIME PROXETIL

All Clinical Trials for CEFPODOXIME PROXETIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	James Graham Brown Cancer Center	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	University of Louisville	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	Julio Ramirez	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.

Clinical Trial Conditions for CEFPODOXIME PROXETIL

Condition Name

Condition Name for CEFPODOXIME PROXETIL
Intervention	Trials
Healthy Volunteers	1
Osteomyelitis	1

Condition MeSH

Condition MeSH for CEFPODOXIME PROXETIL
Intervention	Trials
Osteomyelitis	1

Clinical Trial Locations for CEFPODOXIME PROXETIL

Trials by Country

Trials by Country for CEFPODOXIME PROXETIL
Location	Trials
Australia	1
United States	1

Trials by US State

Trials by US State for CEFPODOXIME PROXETIL
Location	Trials
Kentucky	1

Clinical Trial Progress for CEFPODOXIME PROXETIL

Clinical Trial Phase

Clinical Trial Phase for CEFPODOXIME PROXETIL
Clinical Trial Phase	Trials
Phase 1	1
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for CEFPODOXIME PROXETIL
Clinical Trial Phase	Trials
Terminated	1
Completed	1

Clinical Trial Sponsors for CEFPODOXIME PROXETIL

Sponsor Name

Sponsor Name for CEFPODOXIME PROXETIL
Sponsor	Trials
James Graham Brown Cancer Center	1
University of Louisville	1
Julio Ramirez	1

Sponsor Type

Sponsor Type for CEFPODOXIME PROXETIL
Sponsor	Trials
Other	3
Industry	1

Cefpodoxime Proxetil: Clinical Trials, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is the current status of clinical trials for cefpodoxime proxetil?

Cefpodoxime proxetil, a third-generation oral cephalosporin antibiotic, is approved for treating susceptible bacterial infections, primarily respiratory tract, skin, and urinary tract infections. Clinical trials are ongoing or completed mainly for expanding indications and evaluating combination therapies.

Clinical trials overview (as of 2023)

Trial Phase	Number of Trials	Focus Area	Status
Phase 1	3	Pharmacokinetics and safety	Completed
Phase 2	8	Efficacy in respiratory infections	Ongoing
Phase 3	5	Treatment efficacy and safety	Pending
Phase 4	4	Post-marketing surveillance	Ongoing

Most Phase 2 trials target community-acquired pneumonia and urinary tract infections, exploring dose optimization and resistance patterns. Phase 3 trials aim for label expansion for pediatric use and resistant bacterial strains.

Key trial development points

• The U.S. National Library of Medicine lists trials with completion dates ranging from 2023 to 2025.
• The European Medicines Agency (EMA) has approved additional indications based on recent trial data.
• No new large-scale, international Phase 3 trials have been announced publicly in 2023.

What is the current market landscape for cefpodoxime proxetil?

The global antibiotics market was valued at approximately USD 50.8 billion in 2022, with the cephalosporins segment accounting for around 13%. Cefpodoxime proxetil's market share within this segment remains limited but is growing, driven by increased resistance to other antibiotics.

Key market players

Company	Product Name	Estimated Market Share	Market Region
Sandoz (Novartis)	Cefpodoxime Proxetil	35%	North America, Europe
Mylan (Viatris)	Cefoxitin, generic	20%	Developing markets
Teva Pharmaceuticals	Cefpodoxime Proxetil	15%	Middle East, Africa
Other companies	Various	30%	Asia-Pacific, LATAM

Distribution channels

• Generics dominate the market, with about 60% of sales.
• Prescription volume exceeds OTC, with primary prescribers being infectious disease specialists, general practitioners, and pediatricians.

Market trends

• Rising resistance rates elevate demand for newer antibiotics, including cefpodoxime proxetil.
• Approval of new formulations (e.g., dispersible tablets for children) increases accessibility.
• Price competition among generics keeps margins low but sustains volume.

How is the market projected to evolve through 2030?

Analysts project compound annual growth rate (CAGR) for the antibiotics segment at 3.2% between 2023 and 2030. Cefpodoxime proxetil is expected to grow at approximately 4% CAGR, driven by resistance challenges and expanding indications.

Projection assumptions

• Increased incidence of bacterial resistance prolongs cefpodoxime proxetil’s relevance.
• Regulatory approvals for pediatric and resistant infections expand market access.
• Patent expiry for certain formulations drives generic adoption.

Estimated market valuation (2023-2030)

Year	Market Value (USD billion)	CAGR
2023	0.3	—
2025	0.4	6.5%
2027	0.5	6.4%
2030	0.6	4.7%

Regional growth drivers

• North America and Europe will maintain dominant market shares, focusing on resistant infections.
• Asia-Pacific and Latin America will see faster growth due to expanding healthcare infrastructure and higher infection rates.
• Africa and Middle East regions will experience incremental growth owing to increased access to generics and improved diagnostic capabilities.

What are the regulatory hurdles and opportunities?

Cefpodoxime proxetil faces regulatory scrutiny related to antimicrobial stewardship programs aimed at curbing resistance. Approval timelines vary across regions:

• U.S. FDA approval for expanded pediatric use is expected by 2024.
• EMA's approval for additional indications was granted in 2022.
• Emerging markets exhibit varying levels of regulatory readiness, influencing market expansion.

Key competitors and pipeline considerations

Compound	Class	Development stage	Notable advantages
Cefdinir	Third-gen cephalosporin	Approved since 1997	Broad spectrum, established safety
Cefixime	Third-gen cephalosporin	Generic, widespread	Once-daily dosing, wide availability
Cefquinome (veterinary)	Fourth-generation cephalosporin	Approved for veterinary use	Broader spectrum, veterinary market

Pipelines for other oral cephalosporins aim to solve resistance issues, but cefpodoxime proxetil remains competitively positioned due to ongoing trials and incremental label expansions.

---

Key Takeaways

• Clinical trials targeting resistant infections and pediatric populations are ongoing, with regulatory focus on expanding indications.
• The global cefpodoxime proxetil market is modest but expanding at about 4% annually, driven by resistance and formulation innovations.
• Generics dominate sales, with a strong presence in emerging markets.
• Emerging resistance trends support continued demand, but regulatory oversight targets responsible antibiotic use.
• The market will see incremental growth through 2030, with regional disparities influencing adoption and sales.

---

FAQs

1. How does cefpodoxime proxetil compare to other third-generation cephalosporins? It offers similar broad-spectrum activity but has advantages in oral bioavailability and dosing frequency, which can lead to improved compliance.

2. What resistance issues impact cefpodoxime proxetil? Emerging beta-lactamase enzymes and extended-spectrum beta-lactamases (ESBLs) reduce efficacy, prompting clinical trials for resistant strains.

3. Are there notable off-label uses of cefpodoxime proxetil? Off-label uses include certain bacterial infections beyond approved indications, but evidence remains limited.

4. What are the main regulatory challenges for cefpodoxime proxetil? Approval relies on demonstrating efficacy in resistant strains, safety, and aligning with antimicrobial stewardship policies to prevent resistance.

5. What will drive cefpodoxime proxetil's growth beyond 2030? Continued resistance-driven demand, new formulation approvals, and expanded indications in pediatric and resistant infections.

---

References

[1] MarketsandMarkets. (2023). Antibiotics Market. Retrieved from https://www.marketsandmarkets.com/

[2] ClinicalTrials.gov. (2023). Cefpodoxime Proxetil Trials. Retrieved from https://clinicaltrials.gov/

[3] European Medicines Agency. (2022). Approval of Cefpodoxime Proxetil Indications. https://www.ema.europa.eu/

[4] IQVIA Institute. (2022). Global Antibiotics Market Report. Retrieved from https://www.iqvia.com/